Anal Cancer
Nivolumab after combined modality therapy improves outcomes in high‑risk stage II–IIIB anal cancer.
This UCSF Clinical Trials page highlights ongoing interventional studies for anal cancer, including combination immunotherapy, radiation therapy, chemotherapy, and biomarker research to enhance treatment strategies.
Anal cancer remains a rare but aggressive malignancy; these trials seek to improve survival rates, reduce recurrence, and broaden treatment options for high‑risk patients.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity‑Modulated Radiation Therapy
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Advancements in Immunotherapy for Anal Cancer Treatment
- Background and Current Treatment of Squamous Cell Carcinoma of the Anus
- Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden